Department of Pathology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.
Department of Pathology, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.
Pediatr Dev Pathol. 2020 Mar-Apr;23(2):79-95. doi: 10.1177/1093526619875228. Epub 2019 Sep 25.
Hepatoblastomas (HBs) and pediatric hepatocellular carcinomas (HCCs) together account for almost 80% of primary malignant liver tumors in children and adolescents/young adults. Children's Hepatic International Collaboration (CHIC), Children's Oncology Group (COG), SociétéInternationale d'Oncologie Pédiatrique (SIOP), and International Childhood Liver Tumors Strategy Group trials have contributed to define prognostic factors and risk stratification in these tumors. The recently proposed histologic International Consensus classification of HB and HCC in children based on retrospective analysis from CHIC cases represents the base to define entities with homogeneous clinicopathologic and molecular features. This review will provide a morphologic guide for the upcoming International Liver Tumor treatment trial (Pediatric Hepatic International Tumour Trial) to be conducted through several continents. There will be an emphasis on molecular features and immunohistochemical markers for the definition of the individual histologic subtypes of HB and to better characterize the group of liver tumors in the provisional category of hepatocellular neoplasm-not otherwise specified. A brief overview of HCC in children will also be provided.
肝母细胞瘤 (HBs) 和儿童肝细胞癌 (HCCs) 一起占儿童和青少年/年轻成人原发性肝脏恶性肿瘤的近 80%。儿童肝脏国际协作组织 (CHIC)、儿童肿瘤组 (COG)、国际儿科肿瘤学会 (SIOP) 和国际儿童肝脏肿瘤策略组试验有助于确定这些肿瘤的预后因素和风险分层。最近提出的基于 CHIC 病例回顾性分析的儿童 HB 和 HCC 组织学国际共识分类代表了定义具有同质临床病理和分子特征的实体的基础。这篇综述将为即将在多个大陆进行的国际肝脏肿瘤治疗试验 (儿童肝脏国际肿瘤试验) 提供形态学指南。将重点介绍分子特征和免疫组织化学标志物,以定义 HB 的各个组织学亚型,并更好地描述暂定类别中肝细胞肿瘤的组,即未特指的肝细胞肿瘤。还将简要介绍儿童 HCC。